🟢 Ocugen is trading 9% up today after Q3 revenue topped estimates

Ocugen is trading at $0.80, up 9.07%, after Q3 revenue came in above estimates.

• Q3 revenue was $1.95 million, and Ocugen reported a $0.01 per-share loss; adjusted loss per share beat analyst estimates by $0.05.
• Investors may also be responding to OCU400’s expected Q1 2027 Phase 3 data and cash runway into 2028.
• Biotech-sector strength may provide additional support, with XBI up 2.13%.